Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 8/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027102 | 0.91 | MEN1 (0.31) | KMT2A | |
| SCHEMBL4025759 | 0.87 | KDM2B (0.35) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL4776307 | 0.86 | KDM2B (0.37) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL4023627 | 0.80 | KDM2B (0.39) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL13721312 | 0.80 | KDM2B (0.39) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL4022127 | 0.80 | KDM2B (0.39) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL4023629 | 0.80 | KDM2B (0.39) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL4751954 | 0.80 | DRD4 (0.44) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL4025349 | 0.79 | DRD4 (0.43) | HTTKMT2ACCR3DRD4DRD2 | |
| SCHEMBL4022527 | 0.78 | CARM1 (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | HTT 2084/4885KMT2A 2820/4885CCR3 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.